课题基金 / 基金详情

FRONTOSTRIATAL ACTIVATION IN SUBJECTS AT RISK FOR HUNTINGTON'S DISEASE

FRONTOSTRIATAL ACTIVATION IN SUBJECTS AT RISK FOR HUNTINGTON'S DISEASE
患有亨廷顿病的受试者的额纹状体激活
批准号:
7951015
负责人:
JODY COREY-BLOOM
金额:
$2.04万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-12-01 至 2009-11-30

项目摘要

项目成果

JODY COREY-BLOOM的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是众多研究子项目之一
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To use functional and structural MRI to examine brain changes in subjects at risk for HD prior to significant cell loss by scanning at risk HD subjects and controls at two time-points to: 1) evaluate the hypothesis that functional activation of fronto-striatal circuits is abnormal in subjects at risk for HD compared to controls even while subjects are many years away from manifest disease onset. This will be achieved by comparing at risk HD subjects to controls at timepoint 1. 2) evaluate the hypothesis that alterations in frontostriatal function in HD subjects are detectable over a comparatively short interval (approx. 12 months) by scanning each at risk HD subject and control at two time-points.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FRONTOSTRIATAL ACTIVATION IN SUBJECTS AT RISK FOR HUNTINGTON'S DISEASE
CLINICAL TRIAL: ACR16 VERSUS PLACEBO FOR THE SYMPTOMATIC TREATMENT OF HUNTINGTON
CLINICAL TRIAL: PHASE 3 STUDY OF DIMEBON IN PATIENTS WITH MILD-TO-MODERATE HUNTI
CLINICAL TRIAL: COOPERATIVE HUNTINGTON'S OBSERVATIONAL TRIAL (COHORT)
国内基金
海外基金
分化肌细胞脱细胞ECM-cells sheet 3D 支架构建及其促进容积性肌组织缺损再 生修复应用及机制研究
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
  • 批准号:
    82072862
  • 项目类别:
    面上项目
  • 资助金额:
    56.0万元
  • 批准年份:
    2020
  • 负责人:
    徐云升
  • 依托单位:
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
  • 批准号:
    82070825
  • 项目类别:
    面上项目
  • 资助金额:
    53.0万元
  • 批准年份:
    2020
  • 负责人:
    徐西振
  • 依托单位:
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
  • 批准号:
    81903002
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.5万元
  • 批准年份:
    2019
  • 负责人:
    王斐斐
  • 依托单位: